Cargando…

Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report

Venetoclax with high‐dose methotrexate and rituximab seem effective and safe to treat central nervous system involvement of chronic lymphocytic leukemia.

Detalles Bibliográficos
Autores principales:	Beziat, Guillaume, Gauthier, Martin, Protin, Caroline, Oberic, Lucie, Lerebours, Fleur, Carlier, Jasmine, Ysebaert, Loïc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044374/ https://www.ncbi.nlm.nih.gov/pubmed/32128171 http://dx.doi.org/10.1002/ccr3.2580

Ejemplares similares

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients
por: Protin, Caroline, et al.
Publicado: (2019)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data
por: Beziat, Guillaume, et al.
Publicado: (2020)

Sustained degradation of quality of life in a subgroup of lymphoma survivors: a two-year prospective survey
por: Compaci, Gisèle, et al.
Publicado: (2019)

P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
por: Ysebaert, Loïc, et al.
Publicado: (2023)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
por: Dorcet, Guillaume, et al.
Publicado: (2022)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

Rituximab/methotrexate: Lack of efficacy: case report
Publicado: (2022)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
por: Barbier, Michaela, et al.
Publicado: (2021)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

Rituximab Monotherapy for Grade 2-3 Lymphomatoid Granulomatosis with Central Nervous System Involvement in a Patient Receiving Methotrexate for Rheumatoid Arthritis
por: Hosoi, Hiroki, et al.
Publicado: (2022)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
por: de Vos, S, et al.
Publicado: (2018)

A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis
por: Wang, Zhao, et al.
Publicado: (2020)

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data
por: Le Louedec, Félicien, et al.
Publicado: (2021)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

Methotrexate/prednisone/rituximab: COVID-19 pneumonia: 3 case reports
Publicado: (2021)

Methotrexate/prednisolone/rituximab: COVID-19 pneumonia: 2 case reports
Publicado: (2021)

Not everything is as it seems
por: Biyani, Ghansham, et al.
Publicado: (2020)

TiO(2) pigment prices seem to be holding up remarkably well
Publicado: (2020)

Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient?
por: Ma, Wanlu, et al.
Publicado: (2021)

Caesarean Scar Pregnancy: Single Dose of Intrasac Ultrasound-Guided Methotrexate Injection Seems to be a Safe Option for Treatment
por: Rouvalis, Angeliki, et al.
Publicado: (2023)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China
por: Chen, Cui, et al.
Publicado: (2019)

ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION
por: Ogawa, Takahiro, et al.
Publicado: (2019)

Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease
por: Benedetti, Edoardo, et al.
Publicado: (2023)

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

International perspectives on intensive care at the end-of-life: the futility movement seems alive and well
por: Curtis, J Randall
Publicado: (2003)

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
por: Briani, Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hbt3a7scu565mior5cavbknri6